Trial reportJournal of the American Heart Association2021
Pacemaker-Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study.
Trial report in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pressure-Volume (PV) Measurements for Evaluating Cardiac Parameters Using BackBeat Medical's Cardiac Neuromodulation Therapy (CNT) Pacing Signals in Different Physiological Pacing Sites: An Acute Study
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Pacemaker-Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study.Journal of the American Heart Association · 2021Trial
- Interventional Treatment of Arterial Hypertension in The Modern Era: An Updated Review from the Young Investigator Group of the European Society of Hypertension.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Neuromodulation using Bioelectronics-enabled therapies to combat insulin resistance and its comorbidities.Journal of diabetes and metabolic disorders · 2026Review
- Multimodal, device-based therapeutic targeting of the cardiovascular autonomic nervous system.Nature reviews. Cardiology · 2026Review
- Feasibility and safety of electrohydraulic acoustic therapy for treatment of hypertension in patients with chronic kidney disease.Frontiers in medical technology · 2026Article
- Resistant Blood Pressure: New Frontiers in Interventional Hypertension Therapy.Cardiology and therapy · 2025Review
- Atrioventricular interval modulation therapy for management of hypertension.Heart rhythm O2 · 2025Review
- A scoping review of neuromodulation techniques for controlling blood pressure: what are the ups and downs to this approach?Bioelectronic medicine · 2025Review
- Effects of Atrioventricular Interval Modulation Therapy in Subjects With Hypertension and Diastolic Dysfunction.JACC. Advances · 2025Article
- Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision).Journal of geriatric cardiology : JGC · 2025Article
- Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review.Cureus · 2024Review
- Device's design and clinical perspectives for resistant hypertension therapy.International journal of cardiology. Cardiovascular risk and prevention · 2024Review
- Device-Based Therapy for Resistant Hypertension: An Up-to-Date Review.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022Review
- Review
- A system of real-time neural recording and stimulation and its potential application in blood pressure modulation.Frontiers in medical technology · 2022Article
- Pacemaker-Based Cardiac Neuromodulation Therapy for the Treatment of Hypertension: The New Kid on the Block.Journal of the American Heart Association · 2021Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background In prior unblinded studies, cardiac neuromodulation therapy (CNT) employing a sequence of variably timed short and longer atrioventricular intervals yielded sustained reductions of systolic blood pressure (SBP) in patients with hypertension. The effects of CNT on SBP were investigated in this double-blind randomized pilot study. Methods and Results Eligible patients had daytime ambulatory SBP (aSBP) ≥130 mm Hg and office SBP ≥140 mm Hg despite taking ≥1 antihypertensive medication, and an indication for a dual-chamber pacemaker. Patients underwent Moderato device implantation, which was programmed as a standard pacemaker during a 1-month run-in phase. Patients whose daytime aSBP was ≥125 mm Hg at the end of this period were randomized (1:1, double blind) to treatment (CNT) or control (CNT inactive). The primary efficacy end point was the between-group difference of the change in 24-hour aSBP at 6 months. Of 68 patients initially enrolled and who underwent implantation with the Moderato system, 47 met criteria for study continuation and were randomized (26 treatment, 21 control). The mean age was 74.0±8.7 years, 64% were men, left ventricular ejection fraction was 59.2%±5.7%, and aSBP averaged 141.0±10.8 mm Hg despite the use of 3.3±1.5 antihypertensive medications; 81% had isolated systolic hypertension. Six months after randomization, aSBP was 11.1±10.5 mm Hg (95% CI, -15.2 to -8.1 mm Hg) lower than prerandomization in the treatment group compared with 3.1±9.5 mm Hg (-7.4 to 1.2 mm Hg) lower in controls, yielding a net treatment effect of 8.1±10.1 mm Hg (-14.2 to -1.9 mm Hg) (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.